Clinical Trials Browser

Triple Negative Breast Neoplasms × SGN-LIV1A × 1 year × Clear all

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03310957 2025-12-12

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Phase 1/2 Completed

185 enrolled 23 charts

Breast Neoplasms, Triple Negative Breast Neoplasms